Tesamorelin and 'hello abs': what 10 weeks actually does

What did @forever.fit.kelly actually say?

Kelly claims that after 10 weeks on tesamorelin (which she calls "Tessa"), she developed visible abs at age 45, improved muscle recovery, and slept better, all without changing her workouts or nutrition. She says results didn't show up until weeks five through six, and she describes the outcome as "a real game changer for your physique." To her credit, she repeatedly tells viewers to be patient and doesn't promise overnight results. What she doesn't mention: her dose, whether she was supervised by a clinician, or what her baseline body composition looked like. Those omissions matter a lot when you're talking about a peptide that was FDA-approved for a specific medical condition, not general fat loss in otherwise healthy adults.

Does the science back this up?

Partially, and the distinction is important. Tesamorelin is backed by real clinical evidence, but that evidence is narrow. The short answer is yes, tesamorelin reduces visceral fat, but the research is almost entirely in HIV-positive patients with lipodystrophy, not fit 45-year-old women doing home workouts.

The pivotal FDA-approval trials (Falutz et al., 2010, New England Journal of Medicine) showed statistically significant reductions in visceral adipose tissue (VAT) in HIV patients over 26 weeks. A follow-up analysis (Falutz et al., 2014, Journal of Clinical Endocrinology and Metabolism) confirmed sustained VAT reduction with continued use. These are real findings. But the population studied is so different from Kelly's audience that extrapolating directly is a stretch. Studies in healthy older adults with age-related GH decline are smaller and less definitive. Rudman et al.'s 1990 NEJM work on growth hormone in older men is often cited in this space, but it involved synthetic HGH, not tesamorelin, and has been widely criticized for overstating anti-aging effects.

The sleep and recovery benefits Kelly mentions are plausible. Growth hormone secretagogues can improve slow-wave sleep (Van Cauter et al., 2000, JAMA), which would support the recovery she describes. That part tracks.

What did they get wrong (or right)?

Kelly gets the timeline roughly right, and that's worth acknowledging. She's correct that tesamorelin's effects on body composition are not immediate. The Falutz 2010 data showed meaningful VAT changes appearing around week 8 to 26, so her observation that visible changes started around weeks five to six is plausible, if slightly optimistic.

Where she goes wrong is the attribution problem. She says she kept "nutrition the same" and "the same workouts," implying tesamorelin alone drove her results. That's a significant oversimplification. Body recomposition in a 45-year-old woman is influenced by hormonal status, sleep quality (which she says improved), training consistency, and caloric intake in ways that are genuinely hard to isolate. She has no control condition. This is a classic n=1 confound: she changed at least one variable (the peptide), which itself improved sleep, which affects cortisol, which affects fat storage. Crediting only "Tessa" ignores the cascade.

She also calls it a "game changer for your physique" without any qualification about who this applies to, what supervision is needed, or what the risks are. Side effects including fluid retention, joint pain, and potential effects on glucose metabolism go unmentioned.

What should you actually know?

Tesamorelin is a growth hormone-releasing hormone (GHRH) analog. It works by stimulating the pituitary to release more endogenous growth hormone, which then drives IGF-1 production and promotes lipolysis, particularly in visceral fat. The mechanism is real. The question is whether using it off-label for aesthetic body recomposition in healthy adults is supported by evidence, and the honest answer is: not robustly.

Off-label use is legal when prescribed by a licensed provider, but compounded tesamorelin is not the same as FDA-approved Egrifta. Compounded versions vary in purity and concentration, and no head-to-head equivalency data exists. Anyone considering this should be working with a clinician who has ordered baseline labs including IGF-1, fasting glucose, and HbA1c, since tesamorelin can impair insulin sensitivity (Spooner et al., 2012, AIDS).

• Tesamorelin is FDA-approved only for HIV-associated lipodystrophy.
• Off-label use for general fat loss exists but lacks large-scale RCT support in healthy populations.
• Side effects include edema, arthralgia, and glucose dysregulation.
• Results in Kelly's video cannot be attributed solely to the peptide without a controlled baseline.
• Anyone using this should have ongoing clinical supervision, not just a single consult.